Mahmoud Ghazzi

Over the past 25 years, he has held several executive leadership roles that cover the spectrum of Drug Development including President, Global Development Head, Chief Medical Advisor, Medicine Development Center Head, and Therapeutic Area Head. His most recent role was President, Daiichi-Sankyo Pharmaceutical Development, and Global Development Head, Daiichi-Sankyo Research & Development.

Throughout his career, Dr. Ghazzi has developed portfolios, managed drug development pipelines globally, and advised and led therapeutic area strategies, resources, and talents. He has managed team leaders, physicians, scientists, regulatory strategists, and project managers. Dr. Ghazzi has been responsible for several Global Regulatory submissions and participated in regulatory interactions including Advisory Committee Meetings.

At MMS, Dr. Ghazzi supports internal teams and MMS clients with clinical and regulatory strategy and execution particularly in the areas of cardiovascular and metabolic diseases. He provides independent expert advice for Clinical Development, Regulatory, Safety and Pharmacovigilance, and portfolio strategy including support for drug safety monitoring boards. Dr. Ghazzi earned his MD from the School of Medicine at Damascus University in Syria and a MPH degree, as well as a Ph.D. in Bioengineering, from the University of Michigan.

Suggested For You

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today 

perspectives

January 20th, 2026

Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration 

perspectives

January 13th, 2026

Making Clinical Trial Technology Work in Practice

fact sheet

December 17th, 2025

Advance Psychedelic Drug Development With Proven Regulatory and Data Expertise

fact sheet

December 17th, 2025

Agile Medical Writing Staff Augmentation When You Need Expertise Not Headcount

fact sheet

December 17th, 2025

Biometrics Solutions Fact Sheet: End-to-End Data Expertise for Complex Clinical Trials

whitepaper

December 17th, 2025

Estimands: Opportunity or Risk for Drug Developers?

perspectives

December 16th, 2025

Inside Pharma and Biotech’s Shifting Landscape and the Direction Leaders Are Giving for 2026